US-based cardiac and vascular surgery company CryoLife has acquired Ascyrus Medical in a deal valued at up to $200m.
The deal includes an $80m upfront payment, consisting of $60m in cash and CryoLife common stock worth $20m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition forms part of CryoLife’s strategy to expand presence in the aortic repair market.
Ascyrus is a privately held developer of the aortic arch remodelling device, called Ascyrus Medical Dissection Stent (AMDS), used in the treatment of acute Type A aortic dissections.
Additionally, the deal presents significant cross-selling opportunities for the company with its existing JOTEC portfolio, BioGlue and On-X.
CryoLife CEO, president and chairman Pat Mackin said: “We believe the addition of the AMDS to our product offerings will make a meaningful contribution to our future growth as it gives us immediate access to the combined $100m EU and Canadian markets and has the potential to expand our worldwide addressable market by approximately $540m.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“AMDS is another highly differentiated device that, when included in our commercial channel, will further solidify our position as a global leader in aortic repair as it will immediately strengthen our highly competitive product portfolio in Europe.”
In March, CryoLife obtained the CE Mark for its hybrid stent graft system, E-vita Open NEO, for the treatment of aortic arch disease.
In a separate development, medical contract manufacturer Medbio has acquired Polymer Conversions (PCI).
PCI is a full-service medical device contract manufacturer, which focuses on complex thermoplastic injection moulding and value-added assembly.
The financial terms of the deal were not disclosed.
